These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 19222642)

  • 21. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia].
    Wu W; Li JY; Shen YF; Cao XS; Qiu HR; Xu W
    Zhonghua Nei Ke Za Zhi; 2007 May; 46(5):386-8. PubMed ID: 17637307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia and its significance].
    Xu B; Tian H; Zhou SY
    Ai Zheng; 2004 Oct; 23(10):1218-21. PubMed ID: 15473940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.
    Zagaria A; Anelli L; Albano F; Vicari L; Schiavone EM; Annunziata M; Pane F; Liso V; Rocchi M; Specchia G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):97-102. PubMed ID: 16737907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
    Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
    J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
    Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
    Reid AG; Tarpey PS; Nacheva EP
    Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
    Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
    Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
    J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SOCS-1 gene methylation in chronic myeloid leukemia patients.
    Hatirnaz O; Ure U; Ar C; Akyerli C; Soysal T; Ferhanoğlu B; Ozçelik T; Ozbek U
    Am J Hematol; 2007 Aug; 82(8):729-30. PubMed ID: 17315216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.
    Sakai I; Takeuchi K; Yamauchi H; Narumi H; Fujita S
    Blood; 2002 Oct; 100(8):2926-31. PubMed ID: 12351404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.
    Fourouclas N; Campbell PJ; Bench AJ; Swanton S; Baxter EJ; Huntly BJ; Green AR
    Haematologica; 2006 Jul; 91(7):952-5. PubMed ID: 16818283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative genomic hybridization reveals previously undescribed amplifications and deletions in the chronic myeloid leukemia-derived K-562 cell line.
    Rodley P; McDonald M; Price B; Fright R; Morris C
    Genes Chromosomes Cancer; 1997 May; 19(1):36-42. PubMed ID: 9135993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma.
    Tuncel FC; Serin I; Pehlivan S; Oyaci Y; Pehlivan M
    Blood Res; 2022 Dec; 57(4):250-255. PubMed ID: 36289192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.
    de Souza CA; Pagnano KB; Bendit I; Conchon M; Freitas CM; Coelho AM; Funke VA; Bernardo WM
    Rev Bras Hematol Hemoter; 2012; 34(5):367-82. PubMed ID: 23125546
    [No Abstract]   [Full Text] [Related]  

  • 37. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
    Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
    Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients.
    Ghaith F; Abdou S; El-Bendary A; Shahin D; Eid M; Megeed WA; El-Sheikh I; Farrag W; Yousuf S
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):103-12. PubMed ID: 19222642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.